Walter Strapps
Directeur/Membre du Conseil chez SONA NANOTECH INC.
Fortune : - $ au 30/04/2024
Profil
Walter Strapps is the founder and current Chief Executive Officer of Carver Biosciences, Inc. founded in 2022.
He is also an Independent Director at Sona Nanotech, Inc. since 2022.
Dr. Strapps has held former positions as Director-RNAi Therapeutics at Merck & Co., Inc., Vice President-Discovery Biology at Intellia Therapeutics, Inc., and Chief Scientific Officer at Gemini Therapeutics, Inc. Dr. Strapps has an undergraduate degree from McGill University and a doctorate from Columbia University Vagelos College of Physicians & Surgeons.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SONA NANOTECH, INC.
-.--% | 01/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Walter Strapps
| Sociétés | Poste | Début |
|---|---|---|
| SONA NANOTECH INC. | Directeur/Membre du Conseil | 04/01/2022 |
Carver Biosciences, Inc.
 Carver Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Carver Biosciences, Inc. is a gene therapy company based in Dedham, MA. Carver is developing CRISPR-based therapies for RNA viruses that infect humans, using a programmable platform technology that could offer a generalizable solution for treating many viruses. The company's underlying technology was developed by co-founder Dr. Cameron Myhrvold. Carver Biosciences is leveraging Cas13 to target respiratory viruses at the RNA level, with the aim of destroying the viruses and preventing them from replicating. The company's therapeutics would act in concert with Dr. Uri Lopatin. The company was founded by Cameron Myhrvold and Walter Strapps, with Walter Strapps serving as the CEO since incorporation. | Directeur Général | 01/02/2022 |
Anciens postes connus de Walter Strapps
| Sociétés | Poste | Fin |
|---|---|---|
| GEMI THER | Directeur Technique/Scientifique/R&D | 31/12/2021 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| INTELLIA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Walter Strapps
| McGill University | Undergraduate Degree |
| Columbia University Vagelos College of Physicians & Surgeons | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| SONA NANOTECH INC. | Process Industries |
| Entreprise privées | 2 |
|---|---|
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Carver Biosciences, Inc.
Carver Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Carver Biosciences, Inc. is a gene therapy company based in Dedham, MA. Carver is developing CRISPR-based therapies for RNA viruses that infect humans, using a programmable platform technology that could offer a generalizable solution for treating many viruses. The company's underlying technology was developed by co-founder Dr. Cameron Myhrvold. Carver Biosciences is leveraging Cas13 to target respiratory viruses at the RNA level, with the aim of destroying the viruses and preventing them from replicating. The company's therapeutics would act in concert with Dr. Uri Lopatin. The company was founded by Cameron Myhrvold and Walter Strapps, with Walter Strapps serving as the CEO since incorporation. | Commercial Services |
